Literature DB >> 22780207

Diagnosis, progression patterns and prognostication in mastocytosis.

Wolfgang R Sperr1, Peter Valent.   

Abstract

Mastocytosis is a heterogeneous group of disorders defined by abnormal growth and accumulation of clonal mast cells. CM is the predominant variant in childhood, whereas the majority of adult patients present with systemic mastocytosis. In over 80% of the latter patients, the KIT mutation D816V is detectable. Whereas childhood mastocytosis often resolves spontaneously before adolescence and has a good prognosis, in most adult patients mastocytosis is a persistent systemic disorder. The course and prognosis in these patients are variable; in indolent variants, the clinical course remains stable over years or even decades. In advanced mastocytosis, the prognosis is less favorable despite novel drugs counteracting growth of neoplastic mast cells. Although WHO criteria are clearly separating prognostic subsets of mastocytosis, little is known about specific prognostic factors predicting the outcome in individual patients. In this article, we review current concepts in mastocytosis, including prognostic parameters for indolent and advanced systemic mastocytosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22780207     DOI: 10.1586/ehm.12.12

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  11 in total

1.  Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.

Authors:  Jakub Trizuljak; Wolfgang R Sperr; Lucie Nekvindová; Hanneke O Elberink; Karoline V Gleixner; Aleksandra Gorska; Magdalena Lange; Karin Hartmann; Anja Illerhaus; Massimiliano Bonifacio; Cecelia Perkins; Chiara Elena; Luca Malcovati; Anna B Fortina; Khalid Shoumariyeh; Mohamad Jawhar; Roberta Zanotti; Patrizia Bonadonna; Francesca Caroppo; Alexander Zink; Massimo Triggiani; Roberta Parente; Nikolas von Bubnoff; Akif S Yavuz; Hans Hägglund; Mattias Mattsson; Jens Panse; Nadja Jäkel; Alex Kilbertus; Olivier Hermine; Michel Arock; David Fuchs; Vito Sabato; Knut Brockow; Agnes Bretterklieber; Marek Niedoszytko; Björn van Anrooij; Andreas Reiter; Jason Gotlib; Hanneke C Kluin-Nelemans; Jiri Mayer; Michael Doubek; Peter Valent
Journal:  Allergy       Date:  2020-03-16       Impact factor: 13.146

Review 2.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

Authors:  Peter Valent; Joanna N G Oude Elberink; Aleksandra Gorska; Magdalena Lange; Roberta Zanotti; Björn van Anrooij; Massimiliano Bonifacio; Patrizia Bonadonna; Karoline V Gleixner; Emir Hadzijusufovic; Cecelia Perkins; Karin Hartmann; Anja Illerhaus; Serena Merante; Chiara Elena; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Rosemarie Greul; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Haifa Kathrin Al-Ali; Marie-Anne Morren; Judit Varkonyi; Alexander Zink; Marek Niedoszytko; Dietger Niederwieser; Luca Malcovati; Andreas Reiter; Vanessa Kennedy; Jason Gotlib; Olivier Lortholary; Olivier Hermine; Michel Arock; Hanneke Kluin-Nelemans; Wolfgang R Sperr
Journal:  J Allergy Clin Immunol Pract       Date:  2018-11-08

3.  SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Authors:  Katia Hanssens; Fabienne Brenet; Julie Agopian; Sophie Georgin-Lavialle; Gandhi Damaj; Laure Cabaret; Maria Olivia Chandesris; Paulo de Sepulveda; Olivier Hermine; Patrice Dubreuil; Erinn Soucie
Journal:  Haematologica       Date:  2014-01-03       Impact factor: 9.941

Review 4.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

5.  Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Authors:  Peter Valent; Elisabeth Aberer; Christine Beham-Schmid; Christina Fellinger; Wolfgang Fuchs; Karoline V Gleixner; Rosemarie Greul; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang R Sperr; Friedrich Wimazal; Stefan Wöhrl; Brigitte Zahel; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2013-05-05

6.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 7.  European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Authors:  Peter Valent; Michel Arock; Patrizia Bonadonna; Knut Brockow; Sigurd Broesby-Olsen; Luis Escribano; Karoline V Gleixner; Clive Grattan; Emir Hadzijusufovic; Hans Hägglund; Olivier Hermine; Hans-Peter Horny; Hanneke C Kluin-Nelemans; Marcus Maurer; Marek Niedoszytko; Boguslaw Nedoszytko; Gunnar Nilsson; Hanneke N G Oude-Elberink; Alberto Orfao; Deepti Radia; Andreas Reiter; Frank Siebenhaar; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Jaap J VanDoormaal; Judit Várkonyi; Selim Yavuz; Karin Hartmann
Journal:  Wien Klin Wochenschr       Date:  2012-11-20       Impact factor: 1.704

Review 8.  Targeted Treatment Options in Mastocytosis.

Authors:  Mélanie Vaes; Fleur Samantha Benghiat; Olivier Hermine
Journal:  Front Med (Lausanne)       Date:  2017-07-20

9.  Current concepts on diagnosis and treatment of mastocytosis.

Authors:  D Magliacane; R Parente; M Triggiani
Journal:  Transl Med UniSa       Date:  2014-02-04

10.  Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case.

Authors:  Sassine Ghanem; Gwenalyn Garcia; Liu Ying; Matthew Hurford; Marcel Odaimi
Journal:  Case Rep Oncol Med       Date:  2016-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.